The Group observes 90 years since founding and 20 years of exhibiting at conference
Introduces “One Guerbet” exhibit
Princeton, NJ, November 30, 2016 – Guerbet (FR0000032526 GBT), the global specialist in contrast agents and solutions for medical imaging, this month celebrates its 90th year as a business and 20th year exhibiting at the Radiological Society of North America (RSNA) annual conference. This will be the first year that Guerbet has a fully integrated exhibit space with new products the Group acquired in 2015.
A year after doubling in size following a major acquisition in the United States, the Group continues to grow as one of the leading players in medical imaging worldwide. The Group offers a variety of MRI and X-ray contrast media solutions as well as LF injectors (Guerbet range of injection systems) includeing: a new IllumenaTM for Interventional radiology and Cath Lab; Optistar® for MR; and Optivantage®, OptiOne® and Optistat® for CT.
Guerbet can be found at Booth # 1929
A pioneer and a player in imaging of the future
Although the history of Guerbet dates back to 1901, with the discovery by Marcel Guerbet of the world’s first iodinated contrast agent, the official creation of the pharmaceutical company dates from 15 November 1926. In 1965 it became SA Laboratoires André Guerbet. From a headcount of 150 at that time, its staff grew to 1,000 in 1990, 1,500 in 2015 and 2,600 today, following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago. With this acquisition Guerbet has reached a critical size in each segment and geographical zone with the ambition of entering the world’s top three.
Yves L’Epine, Guerbet CEO: “Guerbet is currently experiencing one of the most exciting periods of growth in its history. Our integrated exhibit space at RSNA is a clear example that now, more than ever, we are driven to offer a full range of indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”
From a business essentially focused on France in the early 1960s, Guerbet developed its international distribution network greatly from the 1970s onwards. Thirty years ago precisely, in 1986, Guerbet entered the stock market (on the Paris Stock Exchange second market) to bolster its development. Since 2005 Guerbet has undertaken a wide-ranging program of industrial site modernization: € 215 million have been devoted to this to ensure the long-term security of its jobs and to bolster its global growth strategy.
Today, Guerbet is truly an international group, with 83% of its sales generated outside France and with four growth drivers: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
In line with this celebration Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences over the coming months.
Events to follow on Twitter: @GuerbetGroup, #Guerbet90
Guerbet is a pioneer in the contrast agent field, with 90 years’ experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €789 million in pro forma revenue in 2015.
For more information about Guerbet, please visit www.guerbet.com
|Guerbet Global||Guerbet US|
|Anne-Laure Delasalle,||Ted Deutsch|
|Communications Director||(609) 578-8765|
|+33 (0)1 45 91 50 email@example.com|